Which has better earnings & valuation, IKT or OLMA?

Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inhibikase Therapeutics N/A N/A -$48.26M -$0.43 N/A Olema Pharmaceuticals N/A N/A -$162.45M -$2.02 N/A

Is IKT or OLMA more profitable?

Inhibikase Therapeutics' return on equity of -41.31% beat Olema Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Inhibikase Therapeutics N/A -41.31% -38.98% Olema Pharmaceuticals N/A -46.00% -41.22%

Which has higher earnings & valuation, ORIC or IKT?

Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oric Pharmaceuticals N/A N/A -$129.47M -$1.44 N/A Inhibikase Therapeutics N/A N/A -$48.26M -$0.43 N/A

Is ORIC or IKT more profitable?

Oric Pharmaceuticals' return on equity of -35.33% beat Inhibikase Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Oric Pharmaceuticals N/A -35.33% -33.31% Inhibikase Therapeutics N/A -41.31% -38.98%

Which has preferable earnings & valuation, IKT or CGEM?

Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inhibikase Therapeutics N/A N/A -$48.26M -$0.43 N/A Cullinan Therapeutics N/A N/A -$219.88M -$3.36 N/A

Is IKT or CGEM more profitable?

Inhibikase Therapeutics' return on equity of -41.31% beat Cullinan Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Inhibikase Therapeutics N/A -41.31% -38.98% Cullinan Therapeutics N/A -51.45% -47.64%

Inhibikase Therapeutics (IKT) Competitors

$1.87 +0.03 (+1.63%)

Closing price 06/23/2026 04:00 PM Eastern

Extended Trading

$1.88 +0.01 (+0.75%)

As of 07:35 AM Eastern

Compare

IKT vs. ETON, OLMA, TBPH, ORIC, and CGEM

Should you buy Inhibikase Therapeutics stock or one of its competitors? MarketBeat compares Inhibikase Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Inhibikase Therapeutics include Eton Pharmaceuticals (ETON), Olema Pharmaceuticals (OLMA), Theravance Biopharma (TBPH), Oric Pharmaceuticals (ORIC), and Cullinan Therapeutics (CGEM). These companies are all part of the "pharmaceutical products" industry.

How does Inhibikase Therapeutics compare to Eton Pharmaceuticals?

Eton Pharmaceuticals (NASDAQ:ETON) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Inhibikase Therapeutics has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -1.70%. Eton Pharmaceuticals' return on equity of -5.68% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	-1.70%	-5.68%	-1.49%
Inhibikase Therapeutics	N/A	-41.31%	-38.98%

Eton Pharmaceuticals presently has a consensus price target of $41.00, indicating a potential upside of 22.42%. Inhibikase Therapeutics has a consensus price target of $5.40, indicating a potential upside of 188.77%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Inhibikase Therapeutics is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	4 Strong Buy rating(s)	3.11

In the previous week, Eton Pharmaceuticals had 3 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 3 mentions for Eton Pharmaceuticals and 0 mentions for Inhibikase Therapeutics. Inhibikase Therapeutics' average media sentiment score of 0.00 beat Eton Pharmaceuticals' score of -0.05 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Eton Pharmaceuticals	Neutral
Inhibikase Therapeutics	Neutral

27.9% of Eton Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 16.5% of Eton Pharmaceuticals shares are owned by insiders. Comparatively, 7.1% of Inhibikase Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Eton Pharmaceuticals has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market.

Eton Pharmaceuticals has higher revenue and earnings than Inhibikase Therapeutics. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$79.95M	11.47	-$4.60M	-$0.07	N/A
Inhibikase Therapeutics	N/A	N/A	-$48.26M	-$0.43	N/A

Summary

Eton Pharmaceuticals beats Inhibikase Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to Olema Pharmaceuticals?

Inhibikase Therapeutics (NASDAQ:IKT) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, dividends, risk, institutional ownership and earnings.

Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	N/A	N/A	-$48.26M	-$0.43	N/A
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A

3.8% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are held by institutional investors. 7.1% of Inhibikase Therapeutics shares are held by insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Inhibikase Therapeutics' return on equity of -41.31% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-41.31%	-38.98%
Olema Pharmaceuticals	N/A	-46.00%	-41.22%

In the previous week, Olema Pharmaceuticals had 1 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 1 mentions for Olema Pharmaceuticals and 0 mentions for Inhibikase Therapeutics. Inhibikase Therapeutics' average media sentiment score of 0.00 beat Olema Pharmaceuticals' score of -1.57 indicating that Inhibikase Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Inhibikase Therapeutics	Neutral
Olema Pharmaceuticals	Very Negative

Inhibikase Therapeutics has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 1.98, meaning that its stock price is 98% more volatile than the broader market.

Inhibikase Therapeutics presently has a consensus price target of $5.40, indicating a potential upside of 188.77%. Olema Pharmaceuticals has a consensus price target of $44.10, indicating a potential upside of 318.80%. Given Olema Pharmaceuticals' higher probable upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Inhibikase Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	4 Strong Buy rating(s)	3.11
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Inhibikase Therapeutics beats Olema Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to Theravance Biopharma?

Inhibikase Therapeutics (NASDAQ:IKT) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

Theravance Biopharma has higher revenue and earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	N/A	N/A	-$48.26M	-$0.43	N/A
Theravance Biopharma	$107.46M	8.14	$105.89M	$2.20	7.71

Inhibikase Therapeutics has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.17, meaning that its stock price is 83% less volatile than the broader market.

Theravance Biopharma has a net margin of 104.34% compared to Inhibikase Therapeutics' net margin of 0.00%. Theravance Biopharma's return on equity of 18.84% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-41.31%	-38.98%
Theravance Biopharma	104.34%	18.84%	10.94%

In the previous week, Theravance Biopharma had 3 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 3 mentions for Theravance Biopharma and 0 mentions for Inhibikase Therapeutics. Inhibikase Therapeutics' average media sentiment score of 0.00 beat Theravance Biopharma's score of -0.05 indicating that Inhibikase Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Inhibikase Therapeutics	Neutral
Theravance Biopharma	Neutral

Inhibikase Therapeutics currently has a consensus target price of $5.40, suggesting a potential upside of 188.77%. Theravance Biopharma has a consensus target price of $21.40, suggesting a potential upside of 26.10%. Given Inhibikase Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Inhibikase Therapeutics is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	4 Strong Buy rating(s)	3.11
Theravance Biopharma	0 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.29

3.8% of Inhibikase Therapeutics shares are owned by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are owned by institutional investors. 7.1% of Inhibikase Therapeutics shares are owned by insiders. Comparatively, 7.7% of Theravance Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Theravance Biopharma beats Inhibikase Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to Oric Pharmaceuticals?

Oric Pharmaceuticals (NASDAQ:ORIC) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

Oric Pharmaceuticals' return on equity of -35.33% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.33%	-33.31%
Inhibikase Therapeutics	N/A	-41.31%	-38.98%

In the previous week, Oric Pharmaceuticals had 1 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 1 mentions for Oric Pharmaceuticals and 0 mentions for Inhibikase Therapeutics. Oric Pharmaceuticals' average media sentiment score of 0.00 equaled Inhibikase Therapeutics'average media sentiment score.

Company	Overall Sentiment
Oric Pharmaceuticals	Neutral
Inhibikase Therapeutics	Neutral

Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A
Inhibikase Therapeutics	N/A	N/A	-$48.26M	-$0.43	N/A

Oric Pharmaceuticals presently has a consensus target price of $18.92, suggesting a potential upside of 112.31%. Inhibikase Therapeutics has a consensus target price of $5.40, suggesting a potential upside of 188.77%. Given Inhibikase Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Inhibikase Therapeutics is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	4 Strong Buy rating(s)	3.11

Oric Pharmaceuticals has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market.

95.1% of Oric Pharmaceuticals shares are held by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are held by institutional investors. 5.7% of Oric Pharmaceuticals shares are held by company insiders. Comparatively, 7.1% of Inhibikase Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Inhibikase Therapeutics beats Oric Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to Cullinan Therapeutics?

Inhibikase Therapeutics (NASDAQ:IKT) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

In the previous week, Cullinan Therapeutics had 2 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 2 mentions for Cullinan Therapeutics and 0 mentions for Inhibikase Therapeutics. Cullinan Therapeutics' average media sentiment score of 0.27 beat Inhibikase Therapeutics' score of 0.00 indicating that Cullinan Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Inhibikase Therapeutics	Neutral
Cullinan Therapeutics	Neutral

Inhibikase Therapeutics' return on equity of -41.31% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-41.31%	-38.98%
Cullinan Therapeutics	N/A	-51.45%	-47.64%

3.8% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are held by institutional investors. 7.1% of Inhibikase Therapeutics shares are held by company insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	N/A	N/A	-$48.26M	-$0.43	N/A
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A

Inhibikase Therapeutics has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of -0.01, suggesting that its share price is 101% less volatile than the broader market.

Inhibikase Therapeutics presently has a consensus price target of $5.40, indicating a potential upside of 188.77%. Cullinan Therapeutics has a consensus price target of $32.00, indicating a potential upside of 80.28%. Given Inhibikase Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Inhibikase Therapeutics is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	4 Strong Buy rating(s)	3.11
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

Inhibikase Therapeutics beats Cullinan Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Inhibikase Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IKT vs. The Competition

Export

Metric	Inhibikase Therapeutics	Biological Products, Except Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$242.94M	$461.63M	$4.34B	$12.30B
Dividend Yield	N/A	N/A	10.93%	5.83%
P/E Ratio	-4.35	N/A	22.07	23.99
Price / Sales	N/A	66.25	151.48	108.06
Price / Cash	N/A	N/A	40.77	54.51
Price / Book	0.81	2.73	18.62	6.50
Net Income	-$48.26M	-$81.71M	$115.37M	$336.88M
7 Day Performance	11.31%	4.05%	-0.47%	-0.16%
1 Month Performance	10.65%	-1.78%	-1.84%	0.76%
1 Year Performance	N/A	N/A	11.97%	28.49%

Inhibikase Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IKT Inhibikase Therapeutics	1.6458 of 5 stars	$1.87 +1.6%	$5.40 +188.8%	N/A	$242.94M	N/A	N/A	6
ETON Eton Pharmaceuticals	4.0556 of 5 stars	$32.15 +1.8%	$41.00 +27.5%	+147.9%	$865.33M	$79.95M	N/A	20
OLMA Olema Pharmaceuticals	1.9106 of 5 stars	$9.88 +0.1%	$44.10 +346.4%	+151.3%	$862.12M	N/A	N/A	70	Negative News
TBPH Theravance Biopharma	2.5192 of 5 stars	$16.32 -1.9%	$21.83 +33.8%	+60.5%	$857.84M	$107.46M	7.42	110
ORIC Oric Pharmaceuticals	1.8753 of 5 stars	$8.40 +1.6%	$18.92 +125.2%	-10.9%	$856.09M	N/A	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IKT) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inhibikase Therapeutics (IKT) Competitors

IKT vs. ETON, OLMA, TBPH, ORIC, and CGEM

How does Inhibikase Therapeutics compare to Eton Pharmaceuticals?

Summary

How does Inhibikase Therapeutics compare to Olema Pharmaceuticals?

Summary

How does Inhibikase Therapeutics compare to Theravance Biopharma?

Summary

How does Inhibikase Therapeutics compare to Oric Pharmaceuticals?

Summary

How does Inhibikase Therapeutics compare to Cullinan Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IKT vs. The Competition

Inhibikase Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Inhibikase Therapeutics (IKT) Competitors

IKT vs. ETON, OLMA, TBPH, ORIC, and CGEM

How does Inhibikase Therapeutics compare to Eton Pharmaceuticals?

Is ETON or IKT more profitable?

Do analysts recommend ETON or IKT?

Does the media favor ETON or IKT?

Do institutionals and insiders believe in ETON or IKT?

Which has more risk & volatility, ETON or IKT?

Which has higher valuation and earnings, ETON or IKT?

Summary

How does Inhibikase Therapeutics compare to Olema Pharmaceuticals?

Which has better earnings & valuation, IKT or OLMA?

Do institutionals & insiders believe in IKT or OLMA?

Is IKT or OLMA more profitable?

Does the media refer more to IKT or OLMA?

Which has more volatility & risk, IKT or OLMA?

Do analysts rate IKT or OLMA?

Summary

How does Inhibikase Therapeutics compare to Theravance Biopharma?

Which has preferable earnings & valuation, IKT or TBPH?

Which has more volatility and risk, IKT or TBPH?

Is IKT or TBPH more profitable?

Does the media refer more to IKT or TBPH?

Do analysts rate IKT or TBPH?

Do insiders and institutionals hold more shares of IKT or TBPH?

Summary

How does Inhibikase Therapeutics compare to Oric Pharmaceuticals?

Is ORIC or IKT more profitable?

Does the media prefer ORIC or IKT?

Which has higher earnings & valuation, ORIC or IKT?

Do analysts prefer ORIC or IKT?

Which has more volatility and risk, ORIC or IKT?

Do institutionals and insiders hold more shares of ORIC or IKT?

Summary

How does Inhibikase Therapeutics compare to Cullinan Therapeutics?

Does the media refer more to IKT or CGEM?

Is IKT or CGEM more profitable?

Do institutionals and insiders believe in IKT or CGEM?

Which has preferable earnings & valuation, IKT or CGEM?

Which has more volatility and risk, IKT or CGEM?

Do analysts prefer IKT or CGEM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IKT vs. The Competition

Inhibikase Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools